Augmenta Bioworks Overview
- Year Founded
-
2016
- Status
-
Acquired/Merged
- Employees
-
2
- Latest Deal Type
-
M&A
Augmenta Bioworks General Information
Description
Developer of novel therapeutics designed to treat rare infectious diseases and profile individual immunity. The company's therapeutics utilize automation, microfluidics, high-throughput DNA sequencing, and scalable computational analysis to identify immune receptors and their antigen specificity that develop antibodies to kill existing viral and bacterial diseases, enabling medical researchers to discover new therapies by understanding the human immune system's protective response to diseases.
Contact Information
Website
www.augbio.comCorporate Office
- 3475 Edison Way
- Unit K
- Menlo Park, CA 94025
- United States
Corporate Office
- 3475 Edison Way
- Unit K
- Menlo Park, CA 94025
- United States
Augmenta Bioworks Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 01-Jan-2024 | Completed | Generating Revenue | |||
| 2. Early Stage VC | Completed | Generating Revenue | ||||
| 1. Accelerator/Incubator | 01-Jan-2016 | Completed | Generating Revenue |
Augmenta Bioworks Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Augmenta Bioworks Patents
Augmenta Bioworks Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230270668-A1 | Dry formulations of anti-sars-cov-2 virus antibodies and compositions and methods of use thereof | Inactive | 11-Oct-2021 | ||
| WO-2023064770-A1 | Dry formulations of anti-sars-cov-2 virus antibodies and compositions and methods of use thereof | Inactive | 11-Oct-2021 | ||
| WO-2023064717-A2 | Antibodies for sars-cov-2 and uses thereof | Inactive | 08-Oct-2021 | ||
| WO-2023064717-A3 | Antibodies for sars-cov-2 and uses thereof | Inactive | 08-Oct-2021 | ||
| US-20210347860-A1 | Antibodies for sars-cov-2 and uses thereof | Active | 11-May-2020 | A61P31/14 |
Augmenta Bioworks Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Augmenta Bioworks Former Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Angel (individual) | Minority | |||
| OS Fund | Venture Capital | Minority | ||
| StartX (US) | Accelerator/Incubator | Minority |
Augmenta Bioworks FAQs
-
When was Augmenta Bioworks founded?
Augmenta Bioworks was founded in 2016.
-
Where is Augmenta Bioworks headquartered?
Augmenta Bioworks is headquartered in Menlo Park, CA.
-
What is the size of Augmenta Bioworks?
Augmenta Bioworks has 2 total employees.
-
What industry is Augmenta Bioworks in?
Augmenta Bioworks’s primary industry is Discovery Tools (Healthcare).
-
Is Augmenta Bioworks a private or public company?
Augmenta Bioworks is a Private company.
-
What is Augmenta Bioworks’s current revenue?
The current revenue for Augmenta Bioworks is .
-
Who are Augmenta Bioworks’s investors?
, OS Fund, and StartX (US) have invested in Augmenta Bioworks.
-
When was Augmenta Bioworks acquired?
Augmenta Bioworks was acquired on 01-Jan-2024.
-
Who acquired Augmenta Bioworks?
Augmenta Bioworks was acquired by Vaxanix.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
